Unlocking the Secrets of Acromegaly: What Incidental Findings Can Tell Us
"A deeper look into how 'accidental' tumor discoveries are reshaping our understanding and treatment of acromegaly."
Acromegaly, a hormonal disorder that results from too much growth hormone (GH) in the body, often presents with noticeable clinical symptoms. However, a subset of cases is discovered incidentally, often during imaging for unrelated conditions. This article explores how these 'accidental' diagnoses are reshaping our understanding and management of acromegaly.
Traditional understanding of acromegaly has been largely based on patients presenting with classic symptoms. But what happens when the condition is caught early, before these symptoms fully manifest? Recent research sheds light on the characteristics of incidentally discovered acromegaly (IA) compared to clinically manifesting acromegaly (CA), offering valuable insights into the disease's progression and optimal treatment strategies.
This article dives into the findings of a comparative analysis that examines the differences between IA and CA, focusing on tumor characteristics, hormonal profiles, and clinical outcomes. We'll also explore how MRI texture analysis can predict tumor behavior, offering a non-invasive tool for assessing recurrence or progression in patients with non-functioning pituitary adenomas (NFPAs).
Acromegaly: prevalence and measurement
A 2023 review reports worldwide acromegaly prevalence of 30–60 cases per million people and an incidence of 2–3 cases per million per year; it also says more than 95% of cases are caused by a sporadic growth-hormone-secreting pituitary adenoma, while fewer than 5% occur in a syndromic or hereditary context. Estimates can depend on how cases are identified: a population-studies review cautions that cancer registries may under-report benign tumors, while data from isolated tertiary referral centers can be affected by selection bias and variation in referral patterns. These differences in methods matter when interpreting population estimates.
Consensus-based diagnosis and care
The 14th Acromegaly Consensus Conference brought together 56 experts from 16 countries to review evidence on biochemical assays, diagnostic criteria, therapeutic efficacy, imaging, pathology, and clinical assessment. Its recommendations advise considering referral to a multidisciplinary pituitary center when biochemical, pathology, or imaging findings are equivocal, or when response to standard treatment is insufficient. A 2025 standards-of-care report notes that international standards for medical management had not been published, and describes an audit intended to report current medical-therapy practices using criteria for Pituitary Tumor Centers of Excellence. A Pituitary Society update also points to patient-centered quality-of-life assessment and the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) as tools relevant to management.
From early descriptions to pituitary origins
Descriptions of giants appeared in lay literature for millennia, but the first attempt at a medical description is attributed to Johannes Wier in 1567. Pierre Marie established the term “acromegaly” in 1886 and described it as a distinct clinical diagnosis. Later clinical descriptions and patient series drew attention to sellar deformation, pituitary enlargement, and pituitary adenomas, while histopathological findings supported the suspected pituitary origin of the condition. By the close of the nineteenth century, clinical observation and pathological investigation had established that connection.
Incidental vs. Clinical Acromegaly: Understanding the Key Differences
A study comparing incidental (IA) and clinically manifesting acromegaly (CA) revealed notable differences between the two groups. Researchers analyzed 69 patients (26 IA and 43 CA) to understand how these groups differ in terms of demographics, tumor characteristics, and clinical presentation.
- Age at Presentation: While not statistically significant, IA patients tended to be slightly younger at presentation (45.58 years) compared to CA patients (50.81 years).
- Tumor Size: IA patients tended to have larger tumors.
- Hormone Levels: Post-OGTT GH levels were significantly lower in IA patients (10.59 mcg/L) compared to CA patients (19.86 mcg/L). Similarly, IGF-1 levels were also lower in IA patients (210.9 %ULN) than in CA patients (361.3 %ULN).
- Tumor Type: Macroadenomas (large tumors) were more common in IA patients (85%) compared to CA patients (70%).
- Gender: Female preponderance was higher in IA patients (69%) compared to CA patients (48%).
- Visual Field Defects: Visual impairments were more common in CA patients.
- Reasons for Referral: IA patients were often referred due to neurological complaints (73%), while CA patients primarily presented with morphometric changes (95%).
- Comorbidities: IA patients were more likely to have mental health disorders and headaches, whereas CA patients were more prone to malignancy, abnormal colonoscopy results, sleep apnea, cardiac abnormalities, sweating, and arthritis.
- Treatment Outcomes: Response to therapy, surgery success rates, need for medication or radiation therapy, and recurrence rates were similar between both groups.
Recent reviews and consensus updates
A November 2025 New England Journal of Medicine review updates the pathophysiology and disease course of acromegaly, emphasizing the general clinician’s role in early diagnosis and management. In April 2026, the 16th Acromegaly Consensus Conference updated recommendations on diagnosis and treatment of comorbidities, drawing on evidence about known and emerging complications and treatment approaches. Separately, a 2025 Nature Reviews Endocrinology overview describes a new era in medical management of pituitary tumors, with novel compounds that directly target tumors showing promise for treatment-refractory or recurrent cases.
Why treatment can fall short
Acromegaly has a broad range of symptoms and comorbidities associated with chronic, progressive growth-hormone elevations, commonly from a pituitary tumor. Successful management may extend beyond treating the hormonal disease itself: many patients are diagnosed late and already have conditions such as cardiovascular disease, diabetes, hypertension, or sleep apnea. These findings underscore the challenges of late recognition and the need to address associated health problems as part of care.
Long-term disease course in reported cases
One report describes an acromegalic patient who refused all treatment modalities; over 30 years, the signs and symptoms of the disease progressed. A separate report concerns a 56-year-old patient with acromegaly treated with conventional radiotherapy. The supplied excerpts do not provide comparable outcomes for these cases, so they illustrate different reported clinical circumstances rather than establishing which approach was more effective.
The Future of Acromegaly Management: Personalized Approaches Based on Early Detection
The identification of distinct characteristics in incidentally discovered acromegaly (IA) is paving the way for more personalized treatment strategies. Early diagnosis, even in the absence of classic symptoms, allows for timely intervention and potentially better long-term outcomes.
Building comparable evidence
Comprehensive national acromegaly databases have appeared over time and make international comparisons possible. However, the source reports that prevalence and incidence rates still vary across datasets. It also identifies a lack of large-scale analysis of geographic and ethnic differences in clinical presentation and management, highlighting an area where further research is needed.
More effective and convenient care
A 2026 review states that some people with acromegaly remain biochemically or clinically uncontrolled despite treatment advances, while others face a high treatment burden. It identifies the development of more effective and convenient treatment options as a continuing need. An updated international consensus on therapeutic outcomes is also the focus of a three-part Pituitary Society podcast series, which explores how clinicians might define disease control, select therapy, and personalize treatment.
A rare disorder with systemic effects
Acromegaly is very rare and is usually caused by a pituitary tumor that produces too much growth hormone. Nearly all pituitary tumors, including those responsible for acromegaly, are benign, but they can grow large and extend beyond the normal boundaries of the pituitary gland. Excess growth hormone and IGF-1 contribute to multisystem manifestations and comorbidities, while early or mild disease can be particularly difficult to recognize and confirm biochemically. The condition is often underdiagnosed and may present at an advanced stage.
Moving forward, integrating advanced imaging techniques like MRI texture analysis can further refine our ability to predict tumor behavior and tailor treatment plans. These tools offer a non-invasive way to assess the risk of recurrence or progression, guiding decisions on surgery, radiation therapy, or medical management.
Ultimately, a comprehensive approach that combines clinical evaluation, hormonal assessment, and advanced imaging will be essential for optimizing care for all acromegaly patients, regardless of how their condition is initially detected. Continued research into the molecular and genetic underpinnings of these tumors will further refine our understanding and lead to even more targeted therapies.